Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barzolvolimab in Chronic Spontaneous Urticaria
NCT05368285Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of barzolvolimab in chronic spontaneous urticaria (CSU), sponsored by Celldex Therapeutics. Started May 2022; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05368285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368285.